<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00507533</url>
  </required_header>
  <id_info>
    <org_study_id>CPAP-2-H</org_study_id>
    <nct_id>NCT00507533</nct_id>
  </id_info>
  <brief_title>Early Application of CPAP in Hematologic</brief_title>
  <acronym>HEMOCPAP</acronym>
  <official_title>Early Application of CPAP in Hematologic Neutropenic Patients Avoid Acute Respiratory Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Turin, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda Ospedaliera San Giovanni Battista</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Turin, Italy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the use of CPAP in the prevention of acute&#xD;
      respiratory failure in neutropenic ( or hematologic malignancy ) patients .CPAP applied&#xD;
      preventively in hematological patients with high risk of ARF may reduce:need for intubations&#xD;
      and mechanical ventilation, incidence of pneumonia and sepsis,mortality,length of ICU and&#xD;
      hospital stay&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Immunocompromised patients with a hematological malignancy that requiring admission in&#xD;
      intensive care unit (ICU) and subsequently mechanical ventilation for respiratory failure was&#xD;
      estimated between 20- 50 per cent of all admitted in hospital.&#xD;
&#xD;
      The survival rate of this patients that requiring mechanical ventilation is very poor.&#xD;
&#xD;
      In many cases the immunodepression with a great improvement in severe complication as&#xD;
      infections , pneumonia, sepsis , is the consequence of our therapy ( chemotherapy , bone&#xD;
      marrow transplantation and stem cell transplantation ) .&#xD;
&#xD;
      Pneumonia is very common cause of mechanical ventilation in about 45-74 per cent of the all&#xD;
      patient with acute respiratory failure (ARF) .&#xD;
&#xD;
      The trial was designed to enroll 40 patients in two groups to demonstrate reduction from 50%&#xD;
      to 10 % of the need of mechanical ventilation , with a type I risk of error of 5% and a power&#xD;
      of 80 %.&#xD;
&#xD;
      Patients were randomized to be treated for four days Venturi mask at a FiO2 of 0.4 (control)&#xD;
      or with oxygen at a FiO2 of 0.4 plus a CPAP of 10 cm H2O (CPAP). At the end of the 4-days&#xD;
      period, patients passed a screening test breathing ambient air. Patients returned to the&#xD;
      assigned treatment if SaO2 less than 95% a.a or respiratory rate more than 25 bpm.CPAP was&#xD;
      generated using a flow generator with an adjustable inspiratory oxygen fraction set to&#xD;
      deliver a flow of up to 140 liters per minute (Whisperflow, Caradyne, Ireland) and a&#xD;
      spring-loaded expiratory pressure valve (Vital Signs Inc, Totoma NJ) and applied using a&#xD;
      latex-free polyvinyl chloride transparent helmet (CaStar, Starmed, Italy) (15); all centers&#xD;
      measured the inspiratory oxygen fraction using an oxygen analyzer (Oxicheck, Caradyne,&#xD;
      Ireland) through the Venturi mask or the helmet.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mechanical ventilation and intubation</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pneumonia , sepsis , ICU LOS , Hospital LOS , Mortality</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hematologic Disease</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Continuous positive airway pressure</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Neutropenic hematological patients ( less than 1000 leukocytes /mm3 ) .&#xD;
&#xD;
          -  SaO2 less than 95% ( a.a.) ,&#xD;
&#xD;
          -  Respiratory rate (RR ) more than 25 breaths/minute .&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  NYHA class II- III- IV or unstable angina or MI&#xD;
&#xD;
          -  Valvular heart disease or cardiac surgery ( previous 3 months)&#xD;
&#xD;
          -  Implanted cardiac pacemaker&#xD;
&#xD;
          -  BMI less than 40&#xD;
&#xD;
          -  History of dilated cardiomyopathy or CPE&#xD;
&#xD;
          -  Severe COPD ( oxygen therapy , recent exacerbation, hypoxemic-hypercapnic to resting ,&#xD;
             FEV1 &lt; 50 %)&#xD;
&#xD;
          -  Diagnosis of sleep or neuromuscular disorders.&#xD;
&#xD;
          -  Claustrophobia .&#xD;
&#xD;
          -  Mechanical ventilation criteria:&#xD;
&#xD;
               -  Severe hypoxemia (arterial oxygen saturation &lt; 80 % with maximal FiO2 )&#xD;
&#xD;
               -  Ph &lt; 7.3 with a PaCO2 &gt; 50 mmHg&#xD;
&#xD;
               -  Signs of patient distress with accessory muscle recruitment and paradoxal abdomen&#xD;
                  movement&#xD;
&#xD;
               -  RR &gt; 35 breaths/minute .&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Squadrone Vincenzo, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Universit√† degli Studi Torino</name>
      <address>
        <city>Turin</city>
        <state>Piemonte</state>
        <zip>10100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <study_first_submitted>July 25, 2007</study_first_submitted>
  <study_first_submitted_qc>July 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2007</study_first_posted>
  <last_update_submitted>February 17, 2009</last_update_submitted>
  <last_update_submitted_qc>February 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2009</last_update_posted>
  <keyword>CPAP</keyword>
  <keyword>Hematologic</keyword>
  <keyword>Neutropenic</keyword>
  <keyword>ARF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

